Form 8-K - Current report:
SEC Accession No. 0001193125-25-035203
Filing Date
2025-02-25
Accepted
2025-02-25 16:34:22
Documents
15
Period of Report
2025-02-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d830999d8k.htm   iXBRL 8-K 24069
2 EX-99.1 d830999dex991.htm EX-99.1 17785
6 GRAPHIC g830999g0225235725221.jpg GRAPHIC 2382
  Complete submission text file 0001193125-25-035203.txt   176935

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20250225.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20250225_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20250225_pre.xml EX-101.PRE 11713
18 EXTRACTED XBRL INSTANCE DOCUMENT d830999d8k_htm.xml XML 3820
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 25663971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)